Healthcare / BiotechnologyHKSE
$11.14
-0.55 (-4.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $30.4M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.3B
P/E
11.9x
↓EV/EBITDA
88.8x
↑ROE
24.9%
↑Gross Margin
94.5%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+57.2%
FCF CAGR
—
FCF margin
44.0%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $158.0M · net income $91.3M · FCF $69.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $158.0M | $158.0M | $38.1M | $89.5M | $40.7M |
| Net Income | $91.3M | $91.3M | $2.8M | $22.8M | $-137.2M |
| EBITDA | $98.1M | $98.1M | $10.1M | $31.2M | $-127.0M |
| EPS | 0.12 | 0.12 | 0.00 | 0.03 | -0.19 |
| Gross Margin | 94.5% | 94.5% | 88.2% | 97.7% | 99.7% |
| Operating Margin | 52.1% | 52.1% | -5.7% | 25.3% | -298.4% |
| Net Margin | 57.8% | 57.8% | 7.3% | 25.5% | -337.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.49 | 0.55 | 0.98 |
| Current Ratio | 5.17 | 5.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $69.6M | $69.6M | $30.4M | $-21.6M | $-118.4M |
| Returns | |||||
| ROE | 24.9% | 24.9% | 2.2% | 19.0% | -147.8% |
| Valuation | |||||
| P/E | 11.85 | 11.85 | 562.16 | 57.33 | — |
| EV/EBITDA | 88.79 | 88.79 | 148.30 | 38.57 | — |
| P/B | 24.60 | 24.60 | 12.91 | 10.64 | 25.46 |
| Growth & Yield | |||||
| Revenue Growth | 314.6% | 314.6% | -57.4% | 120.1% | — |
| EPS Growth | 3143.2% | 3143.2% | -87.7% | 115.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
102.0%
EPS terminal req.
$0.99
Spread vs growth
3041.3%
5Y implied EPS CAGR
58.4%
EPS terminal req.
$1.20
Spread vs growth
3084.9%
10Y implied EPS CAGR
32.0%
EPS terminal req.
$1.93
Spread vs growth
3111.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.4%
Start / end P/E
2381.1x → 92.8x
EPS bridge
0.00 → 0.12
Residual
-3020.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.